News
New Spectroscopic Method Developed for Quantifying Diclofenac and Methocarbamol in Tablets
Researchers have developed a novel spectroscopic method for quantifying diclofenac and methocarbamol in tablets. The new method uses first derivative synchronous fluorescence spectroscopy (FDSFS).
A new method has been developed for the simultaneous quantification of diclofenac and methocarbamol in tablets, according to a Scientific Reports manuscript. Diclofenac, a nonsteroidal anti-inflammatory drug, and methocarbamol, a muscle relaxant, are often used in combination to treat muscle spasms. The novel method uses first derivative synchronous fluorescence spectroscopy (FDSFS). According to the report, the most effective results were achieved with a wavelength difference of 60 nm, using water as a diluting solvent. Diclofenac was measured at 288 nm, while methocarbamol was measured at 346 nm. The manuscript is an unedited version and may contain errors.
Key Facts
- The method uses first derivative synchronous fluorescence spectroscopy (FDSFS).
- The method is for quantifying diclofenac and methocarbamol in tablets.
- The diclofenac detection limit was 0.15 µg/mL, with a quantitation limit of 0.30 µg/mL.
- The methocarbamol detection limit was 0.17 µg/mL, with a quantitation limit of 0.34 µg/mL.
- The most effective results were achieved with a wavelength difference of 60 nm, using water as a diluting solvent.
- Diclofenac was measured at 288 nm.
- Methocarbamol was measured at 346 nm.